leflunomide has been researched along with Kahler Disease in 5 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The inexpensive, well-tolerated, immunomodulatory agent leflunomide, used extensively for the treatment of rheumatoid arthritis, has been shown to produce significant activity against multiple myeloma (MM) in pre-clinical studies." | 9.34 | Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. ( Buettner, R; Chowdhury, A; Duarte, L; Forman, SJ; Hammond, SN; Htut, M; Karanes, C; Krishnan, A; Nathwani, N; Palmer, J; Pichiorri, F; Rosen, ST; Rosenzweig, M; Sahebi, F; Sanchez, JF; Synold, T; Tao, S; Tsai, NC; Wu, X, 2020) |
| "Leflunomide, an anti-inflammatory agent, has been shown to be effective in multiple myeloma (MM) treatment; however, the mechanism of this phenomenon has not been fully elucidated." | 8.02 | The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line. ( Adamczuk, G; Adamczuk, K; Humeniuk, E; Iwan, M; Korga-Plewko, A; Natorska-Chomicka, D, 2021) |
| "Multiple myeloma is still an incurable disease; therefore, new therapeutics are urgently needed." | 5.35 | Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. ( Adam, C; Baumann, P; Bumeder, I; Mandl-Weber, S; Oduncu, F; Schmidmaier, R; Völkl, A, 2009) |
| "The inexpensive, well-tolerated, immunomodulatory agent leflunomide, used extensively for the treatment of rheumatoid arthritis, has been shown to produce significant activity against multiple myeloma (MM) in pre-clinical studies." | 5.34 | Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. ( Buettner, R; Chowdhury, A; Duarte, L; Forman, SJ; Hammond, SN; Htut, M; Karanes, C; Krishnan, A; Nathwani, N; Palmer, J; Pichiorri, F; Rosen, ST; Rosenzweig, M; Sahebi, F; Sanchez, JF; Synold, T; Tao, S; Tsai, NC; Wu, X, 2020) |
| "Leflunomide, an anti-inflammatory agent, has been shown to be effective in multiple myeloma (MM) treatment; however, the mechanism of this phenomenon has not been fully elucidated." | 4.02 | The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line. ( Adamczuk, G; Adamczuk, K; Humeniuk, E; Iwan, M; Korga-Plewko, A; Natorska-Chomicka, D, 2021) |
| "Multiple myeloma is still an incurable disease; therefore, new therapeutics are urgently needed." | 1.35 | Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. ( Adam, C; Baumann, P; Bumeder, I; Mandl-Weber, S; Oduncu, F; Schmidmaier, R; Völkl, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamczuk, G | 1 |
| Humeniuk, E | 1 |
| Iwan, M | 1 |
| Natorska-Chomicka, D | 1 |
| Adamczuk, K | 1 |
| Korga-Plewko, A | 1 |
| Rosenzweig, M | 1 |
| Palmer, J | 2 |
| Tsai, NC | 1 |
| Synold, T | 1 |
| Wu, X | 2 |
| Tao, S | 1 |
| Hammond, SN | 1 |
| Buettner, R | 2 |
| Duarte, L | 1 |
| Htut, M | 1 |
| Karanes, C | 1 |
| Nathwani, N | 1 |
| Pichiorri, F | 2 |
| Sahebi, F | 1 |
| Sanchez, JF | 2 |
| Chowdhury, A | 1 |
| Krishnan, A | 2 |
| Forman, SJ | 1 |
| Rosen, ST | 2 |
| Morales, C | 1 |
| Caserta, E | 1 |
| Troadec, E | 1 |
| Gunes, EG | 1 |
| Viola, D | 1 |
| Khalife, J | 1 |
| Li, H | 1 |
| Keats, JJ | 1 |
| Christofferson, A | 1 |
| Synold, TW | 1 |
| Pozhitkov, A | 1 |
| Vaidehi, N | 1 |
| Marcucci, G | 1 |
| Rosenzweig, MA | 1 |
| Baumann, P | 1 |
| Mandl-Weber, S | 1 |
| Völkl, A | 1 |
| Adam, C | 1 |
| Bumeder, I | 1 |
| Oduncu, F | 1 |
| Schmidmaier, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma[NCT02509052] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2015-12-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Stringent complete response [sCR]/complete response [CR]/very good partial response [VGPR]/or partial response [PR]), assessed by International Myeloma Working Group (IMWG) criteria. (NCT02509052)
Timeframe: From the start of treatment until disease progression/recurrence, assessed up to 48 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: 20 mg Leflunomide | 3 |
| Arm 2: 40 mg Leflunomide | 3 |
| Arm 3: 60 mg Leflunomide | 3 |
Clinical benefit response rate (sCR/CR/VGPR/partial response [PR]/minimal response [MR] or stable disease [SD]), assessed by International Myeloma Working Group (IMWG) criteria (NCT02509052)
Timeframe: From the start of treatment until disease progression/recurrence, assessed up to 48 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: 20 mg Leflunomide | 3 |
| Arm 2: 40 mg Leflunomide | 3 |
| Arm 3: 60 mg Leflunomide | 3 |
Observed toxicities will be summarized, for all dose levels, in terms of type (organ affected or laboratory determination), severity, time of onset, duration, serum concentration of the active leflunomide metabolite, probable association with the study treatment and reversibility or outcome. (NCT02509052)
Timeframe: 28 days
| Intervention | mg (Number) |
|---|---|
| All Participants | 60 |
Median and range of nine patients with Complete Response (CR) (NCT02509052)
Timeframe: Assessed up to 48 months
| Intervention | days (Median) |
|---|---|
| Arm 1: 20 mg Leflunomide | 336 |
| Arm 2: 40 mg Leflunomide | 112 |
| Arm 3: 60 mg Leflunomide | 54 |
Number of patients with Stable Disease greater than or equal to 90 days (NCT02509052)
Timeframe: Assessed at ninety days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: 20 mg Leflunomide | 2 |
| Arm 2: 40 mg Leflunomide | 3 |
| Arm 3: 60 mg Leflunomide | 0 |
1 trial available for leflunomide and Kahler Disease
| Article | Year |
|---|---|
Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Repositioning; Humans; Leflunomide; Multiple My | 2020 |
4 other studies available for leflunomide and Kahler Disease
| Article | Year |
|---|---|
The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Crotonates; Enzyme Inhib | 2021 |
Buettner R, Morales C, Caserta E, et al. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Adv. 2019;3(7):1027-1032.
Topics: Humans; Leflunomide; Multiple Myeloma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1 | 2022 |
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.
Topics: Animals; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Leflunomide; Lenalido | 2019 |
Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Adhesion Molecules; Cel | 2009 |